0001628280-26-055765 | 10-Q | XBRL Viewer

Marketable Securities

6 Months Ended

Jun. 30, 2026

Investments, Debt and Equity Securities [Abstract]

The fair value of available-for-sale marketable securities by type of security was as follows (in thousands):


	June 30, 2026
	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Marketable Securities:
U.S. Treasury Bills with original maturity of one year or less	$	134,091	$	—	$	(40)	$	134,051
U. S. Treasury Bills with original maturity of one to two years	267,135		—		(526)		266,609
Total marketable securities	$	401,226	$	—	$	(566)	$	400,660


	December 31, 2025
	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Marketable Securities:
U.S. Treasury Bills with original maturity of one year or less	$	233,672	$	146	$	—	$	233,818
U.S. Treasury Bills with original maturity of one to two years	84,201		97		—		84,298
Total marketable securities	$	317,873	$	243	$	—	$	318,116

The following table summarizes the Company's available-for-sale securities in an unrealized loss position, aggregated by type and length of time in a continuous unrealized position (in thousands):


	June 30, 2026
	Less than 12 Months				12 Months or Longer				Total
	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
Marketable Securities:
U.S. Treasury Bills	$	400,660	$	(566)	$	—	$	—	$	400,660	$	(566)
Total	$	400,660	$	(566)	$	—	$	—	$	400,660	$	(566)

As summarized in the tables immediately above, the Company held nineteen debt securities that were in an unrealized loss position as of June 30, 2026. The unrealized losses at June 30, 2026 were attributable to changes in interest rates and do not represent credit losses. The Company does not intend to sell these securities, and it is not more likely than not that it will be required to sell them before recovery of their amortized cost basis. The Company held no debt securities that were in an unrealized loss position as of December 31, 2025.

Description of Business, Organization, and Liquidity	6 Months Ended
Description of Business, Organization, and Liquidity	Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business, Organization, and Liquidity	Description of Business, Organization, and Liquidity Bicara Therapeutics Inc. (“Bicara” or the “Company”) was incorporated in the state of Delaware in December 2018 and is a clinical-stage biopharmaceutical company based in Boston, Massachusetts. The Company is committed to bringing transformative bifunctional therapies to patients with solid tumors. Its lead program ficerafusp alfa is a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to a human transforming growth factor beta ligand trap. Since inception, the Company has operated in the preclinical and clinical stages and has devoted substantially all of its time and efforts to performing research and development activities, raising capital, and recruiting management and technical staff to support these operations. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, risks associated with the successful research, development and manufacturing of product candidates, competition from other companies, dependence on key personnel, protection of intellectual property, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if our product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. The Company historically has funded its operations from the issuance of common stock in connection with its initial public offering (“IPO”), issuance of common stock in connection with its at-the-market offering program (the “ATM Program”), issuance of equity securities in a public offering in February 2026, redeemable convertible preferred stock and through debt financing. On September 16, 2024, the Company closed its IPO, through which it issued 20,125,000 shares of common stock with par value of $0.0001 per share and a purchase price of $18.00 per share. The Company raised net proceeds of $332.4 million from the issuance of common stock. In December 2025, the Company issued 1,604,000 shares of common stock with par value of $0.0001 per share through the ATM Program and raised net proceeds of $29.5 million. In February 2026, the Company issued and sold 8,581,250 shares of its common stock, including 1,406,250 shares pursuant to the exercise of the underwriters’ option to purchase additional shares, at a price to the public of $16.00 per share. Further, in lieu of common stock to certain investors, the Company sold pre-funded warrants to purchase 2,200,000 shares of common stock at a public offering price of $15.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. As a result of the offering, the Company received approximately $161.8 million in net proceeds. The Company has incurred operating losses since inception and expects such losses and negative operating cash flows to continue for the foreseeable future. As of June 30, 2026, the Company had cash, cash equivalents and marketable securities of $497.3 million and an accumulated deficit of $470.6 million . The Company expects that its cash, cash equivalents and marketable securities as of June 30, 2026 of $497.3 million will be sufficient to fund the operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these unaudited condensed consolidated financial statements.

Defined Contribution Plan	6 Months Ended
Defined Contribution Plan	Jun. 30, 2026
Retirement Benefits [Abstract]
Defined Contribution Plan	Defined Contribution PlanThe Company currently maintains a tax-qualified 401(k) retirement savings plan for our employees. All eligible employees are able to participate in the plan beginning one month after their first day of employment. Under our defined contribution plan, employees may elect to defer a percentage of their compensation per year, subject to a maximum limit prescribed by tax law, and the Company match a portion of their eligible contributions. The Company provided matching discretionary contributions under the 401(k) plan of $0.2 million and $0.1 million for the three months ended June 30, 2026 and June 30, 2025, respectively. The Company provided matching discretionary contributions under the 401(k) plan of $0.4 million and $0.2 million for the six months ended June 30, 2026 and June 30, 2025, respectively.

Stockholder's Equity (Details) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended
	Oct. 03, 2025	Feb. 28, 2026	Dec. 31, 2025	Jun. 30, 2026
Class of Stock [Line Items]
Preferred stock, shares authorized (in shares)			10,000,000	10,000,000
Preferred stock, par value (in usd per share)			$ 0.0001	$ 0.0001
Preferred stock, shares issued (in shares)			0	0
Preferred stock, shares outstanding (in shares)			0	0
Common stock, shares authorized (in shares)			500,000,000	500,000,000
Common stock, par value (in usd per share)			$ 0.0001	$ 0.0001
Common stock, shares issued (in shares)			56,600,724	65,931,128
Common stock, shares outstanding (in shares)			56,600,724	65,931,128
Registration payment arrangement, maximum potential consideration	$ 400.0
Pre-Funded Warrants
Class of Stock [Line Items]
Common stock, par value (in usd per share)		$ 0.0001
February 2026 Offering \| Pre-Funded Warrants
Class of Stock [Line Items]
Class of warrant or right, number of securities called by warrants or rights (in shares)		2,200,000
Class of warrant or right, exercise price of warrants or rights (in usd per share)		$ 15.9999
Difference in offering price from common stock (in usd per share)		$ 0.0001
Over-Allotment Option
Class of Stock [Line Items]
Number of shares issued in transaction (in shares)		1,406,250
ATM Program
Class of Stock [Line Items]
Common stock, par value (in usd per share)			$ 0.0001
Number of shares issued in transaction (in shares)			1,604,000
Registration payment arrangement, maximum potential consideration	$ 150.0
Sale of stock, commission fee percentage	3.00%
Common stock, capital shares reserved for future issuance (in shares)				120,000,000.0
Common Equity \| February 2026 Offering
Class of Stock [Line Items]
Number of shares issued in transaction (in shares)		8,581,250
Public offering price (in usd per share)		$ 16.00

Accrued Expenses and Other Current Liabilities (Tables)

6 Months Ended

Jun. 30, 2026

Payables and Accruals [Abstract]

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	June 30, 2026		December 31, 2025

Accrued research and development expenses	$	28,179	$	13,085
Accrued bonus and payroll related expenses	4,052		5,041
Accrued professional fees	1,315		591
Accrued other	120		181
Total	$	33,666	$	18,898

Summary of Significant Accounting Policies (Details)	3 Months Ended		6 Months Ended
Summary of Significant Accounting Policies (Details)	Jun. 30, 2026 shares	Jun. 30, 2025 shares	Jun. 30, 2026 segment shares	Jun. 30, 2025 shares	Feb. 28, 2026 shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of operating segments \| segment			1
Share-Based Payment Arrangement
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Options outstanding (in shares)	11,737,518	8,797,689	11,737,518	8,797,689
Pre-Funded Warrants \| February 2026 Offering
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Class of warrant or right, number of securities called by warrants or rights (in shares)					2,200,000

Defined Contribution Plan (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
Defined Contribution Plan (Details) - USD ($) $ in Millions	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Retirement Benefits [Abstract]
Defined contribution, plan cost	$ 0.2	$ 0.1	$ 0.4	$ 0.2

Marketable Securities (Tables)

6 Months Ended

Jun. 30, 2026

Investments, Debt and Equity Securities [Abstract]

Schedule of Available-For-Sale Investments by Type of Security

The fair value of available-for-sale marketable securities by type of security was as follows (in thousands):


	June 30, 2026
	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Marketable Securities:
U.S. Treasury Bills with original maturity of one year or less	$	134,091	$	—	$	(40)	$	134,051
U. S. Treasury Bills with original maturity of one to two years	267,135		—		(526)		266,609
Total marketable securities	$	401,226	$	—	$	(566)	$	400,660


	December 31, 2025
	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Marketable Securities:
U.S. Treasury Bills with original maturity of one year or less	$	233,672	$	146	$	—	$	233,818
U.S. Treasury Bills with original maturity of one to two years	84,201		97		—		84,298
Total marketable securities	$	317,873	$	243	$	—	$	318,116

Schedule of Available-For-Sale Securities in an Unrealized Loss Position

The following table summarizes the Company's available-for-sale securities in an unrealized loss position, aggregated by type and length of time in a continuous unrealized position (in thousands):


	June 30, 2026
	Less than 12 Months				12 Months or Longer				Total
	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
Marketable Securities:
U.S. Treasury Bills	$	400,660	$	(566)	$	—	$	—	$	400,660	$	(566)
Total	$	400,660	$	(566)	$	—	$	—	$	400,660	$	(566)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Common Equity	Additional Paid in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2024		54,440,013
Beginning balance at Dec. 31, 2024	$ 491,875	$ 7	$ 712,884		$ (221,016)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		88,962
Issuance of common stock upon exercise of stock options	477		477
Stock-based compensation	3,451		3,451
Net loss	(36,846)				(36,846)
Ending balance (in shares) at Mar. 31, 2025		54,528,975
Ending balance at Mar. 31, 2025	458,957	$ 7	716,812		(257,862)
Beginning balance (in shares) at Dec. 31, 2024		54,440,013
Beginning balance at Dec. 31, 2024	491,875	$ 7	712,884		(221,016)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(64,234)
Ending balance (in shares) at Jun. 30, 2025		54,556,078
Ending balance at Jun. 30, 2025	435,196	$ 7	720,439		(285,250)
Beginning balance (in shares) at Mar. 31, 2025		54,528,975
Beginning balance at Mar. 31, 2025	458,957	$ 7	716,812		(257,862)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		27,103
Issuance of common stock upon exercise of stock options	135		135
Stock-based compensation	3,492		3,492
Net loss	(27,388)				(27,388)
Ending balance (in shares) at Jun. 30, 2025		54,556,078
Ending balance at Jun. 30, 2025	$ 435,196	$ 7	720,439		(285,250)
Beginning balance (in shares) at Dec. 31, 2025	56,600,724	56,600,724
Beginning balance at Dec. 31, 2025	$ 401,452	$ 7	760,168	$ 243	(358,966)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, and accompanying pre-funded warrants, net of offering cost (in shares)		8,581,250
Issuance of common stock, and accompanying pre-funded warrants, net of issuance cost	161,763	$ 1	161,762
Issuance of common stock upon exercise of stock options (in shares)		365,063
Issuance of common stock upon exercise of stock options	1,582		1,582
Stock-based compensation	5,858		5,858
Unrealized loss on marketable securities, net of tax	(486)			(486)
Net loss	(56,211)				(56,211)
Ending balance (in shares) at Mar. 31, 2026		65,547,037
Ending balance at Mar. 31, 2026	$ 513,958	$ 8	929,370	(243)	(415,177)
Beginning balance (in shares) at Dec. 31, 2025	56,600,724	56,600,724
Beginning balance at Dec. 31, 2025	$ 401,452	$ 7	760,168	243	(358,966)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	749,154
Net loss	$ (111,647)
Ending balance (in shares) at Jun. 30, 2026	65,931,128	65,931,128
Ending balance at Jun. 30, 2026	$ 468,768	$ 8	939,940	(567)	(470,613)
Beginning balance (in shares) at Mar. 31, 2026		65,547,037
Beginning balance at Mar. 31, 2026	513,958	$ 8	929,370	(243)	(415,177)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		384,091
Issuance of common stock upon exercise of stock options	2,332		2,332
Stock-based compensation	8,238		8,238
Unrealized loss on marketable securities, net of tax	(324)			(324)
Net loss	$ (55,436)				(55,436)
Ending balance (in shares) at Jun. 30, 2026	65,931,128	65,931,128
Ending balance at Jun. 30, 2026	$ 468,768	$ 8	$ 939,940	$ (567)	$ (470,613)

Stock-Based Compensation - Schedule of Stock Options Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2026
Shares
Beginning balance (in shares)	9,850,977
Granted (in shares)	3,071,020
Exercised (in shares)	(749,154)
Canceled (in shares)	(435,325)
Ending balance (in shares)	11,737,518
Weighted- Average Exercise Price
Beginning balance (in usd per share)	$ 9.03
Granted (in usd per share)	17.89
Exercised (in usd per share)	5.22
Canceled (in usd per share)	11.55
Ending balance (in usd per share)	$ 11.50
Stock Options Additional Disclosures
Weighted Average – Remaining Contractual Life (years), Outstanding	8 years 6 months 21 days
Aggregate Intrinsic Value, Outstanding	$ 213,544
Shares, Exercisable (in shares)	3,823,103
Weighted-Average Exercise Price, Exercisable (in usd per share)	$ 8.03
Weighted Average – Remaining Contractual Life (years), Exercisable	7 years 10 months 2 days
Aggregate Intrinsic Value, Exercisable	$ 82,818
Shares, Exercisable and expected to vest (in shares)	11,737,518
Weighted- Average Exercise Price, Exercisable and expected to vest (in usd per share)	$ 11.50
Weighted Average – Remaining Contractual Life (years), Exercisable and expected to vest	8 years 6 months 21 days

Marketable Securities - Schedule of Available-For-Sale Investments by Type of Security (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]
Amortized Cost	$ 401,226	$ 317,873
Unrealized Gains	0	243
Unrealized Losses	(566)	0
Fair Value	400,660	318,116
U.S. Treasury Bills with original maturity of one year or less
Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]
Amortized Cost	134,091
Unrealized Gains	0
Unrealized Losses	(40)
U. S. Treasury Bills with original maturity of one to two years
Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]
Amortized Cost	267,135
Unrealized Gains	0
Unrealized Losses	(526)
U.S. Treasury Bills \| U.S. Treasury Bills with original maturity of one year or less
Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]
Amortized Cost	134,091	233,672
Unrealized Gains	0	146
Unrealized Losses	(40)	0
Fair Value	134,051	233,818
U.S. Treasury Bills \| U. S. Treasury Bills with original maturity of one to two years
Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]
Amortized Cost	267,135	84,201
Unrealized Gains	0	97
Unrealized Losses	(526)	0
Fair Value	$ 266,609	$ 84,298

Significant Agreements	6 Months Ended
Significant Agreements	Jun. 30, 2026
Commitments and Contingencies Disclosure [Abstract]
Significant Agreements	Significant Agreements IQVIA On October 15, 2019, the Company entered into a master clinical contract services agreement with IQVIA RDS Inc. (“IQVIA”), which was amended in December 2023 to include global clinical trials. Pursuant to the terms of the agreement, as amended, IQVIA will provide the Company with certain global clinical-development related services and laboratory services under separately executed statements of work (“SOWs”). In June 2021, the Company entered into an SOW with IQVIA for lab and clinical development services, to be invoiced on a monthly basis based on work performed by IQVIA. Under this SOW, Bicara agreed to provide IQVIA with an initial upfront payment of $1.8 million, of which $1.0 million was a refundable deposit and $0.8 million for investigator grant payment in advance. In December 2022, Bicara entered into an authorized to proceed agreement (“ATP”) with IQVIA. Under the ATP, Bicara agreed to provide IQVIA with an additional refundable deposit of $0.9 million, which was paid in March 2023. Both the initial deposit and the ATP deposit will be held on account and reconciled against final invoices. As of June 30, 2026 and December 31, 2025, the refundable deposit balance was $1.9 million, which is included within other assets on the balance sheets. On December 18, 2024, the Company entered into a second SOW, as amended in April 2026 (the “second SOW”), for lab and clinical development services with IQVIA, which was incorporated into the master clinical contract services agreement and part of the Company’s FORTIFI-HN01 Phase 2/3 clinical trial. Services will be invoiced on a monthly basis based on work performed by IQVIA. Under the second SOW, Bicara agreed to provide IQVIA with an initial upfront payment of $12.8 million, of which $7.3 million was for investigator grant payments made in advance, $4.5 million was a deposit for IQVIA direct services and $1.0 million was a deposit for pass through costs. The deposits will be held on account with an incremental return starting the month after 75% of the budgeted costs has been paid by the Company. Under the second SOW, IQVIA is eligible to receive potential additional payments and it is subject to potential penalties based on certain milestone targets. For the three months ended June 30, 2026 and 2025, the Company incurred $17.3 million and $8.8 million in expenses, respectively and paid $9.2 million and $5.2 million, respectively, to IQVIA. For the six months ended June 30, 2026 and 2025 the Company incurred $27.1 million and $16.8 million in expenses, respectively and paid $16.9 million and $17.5 million, respectively, to IQVIA. As of June 30, 2026 and December 31, 2025, the Company had $1.3 million and $0.4 million classified in accounts payable, respectively, and $20.0 million and $8.6 million classified in accrued expenses and other current liabilities on the balance sheets. Clinical Trial Collaboration and Supply Agreement with MSD On May 19, 2022, we entered into a Clinical Trial Collaboration and Supply Agreement (the "MSD Agreement") with MSD International GmbH ("MSDIG"), and MSD International Business GmbH ("MSDIB" and collectively with MSDIG, "MSD"). Pursuant to the MSD Agreement, we provide ficerafusp alfa and MSD provides pembrolizumab to be used in combination in a clinical trial sponsored by us. The clinical trial is a First-in-Human, Phase 1/1b, Open-label, Multicenter Study intended to characterize the safety, tolerability and recommended dose of single agent ficerafusp alfa and combination ficerafusp alfa plus pembrolizumab. To facilitate such collaboration activities and information exchange and pursuant to the MSD Agreement, we and MSD created a joint development committee with an equal number of representatives from each party. Pursuant to the MSD Agreement, all clinical data resulting from the portion of the clinical trial involving the combination of ficerafusp alfa and pembrolizumab is jointly owned by both us and MSD. We own all clinical data resulting from the part of the clinical trial involving ficerafusp alfa alone or in combination with other treatments that are not pembrolizumab, and MSD owns all clinical data resulting from the part of the clinical trial involving pembrolizumab alone or in combination with other treatments that are not ficerafusp alfa. There are no accounting considerations for this agreement.

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - $ / shares	Jun. 30, 2026	Dec. 31, 2025
Statement of Financial Position [Abstract]
Preferred stock, par value (in usd per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in usd per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	65,931,128	56,600,724
Common stock, shares outstanding (in shares)	65,931,128	56,600,724

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Related Party Transaction [Line Items]
Accrued research and development expenses	$ 28,179	$ 13,085
Accrued bonus and payroll related expenses	4,052	5,041
Accrued professional fees	1,315	591
Accrued other	120	181
Nonrelated Party
Related Party Transaction [Line Items]
Total	$ 33,666	$ 18,898

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets
Cash and cash equivalents	$ 96,599	$ 96,685
Prepaid expenses and other assets	6,561	7,252
Marketable securities	400,660	318,116
Total current assets	503,820	422,053
Property and equipment, net	362	330
Right of use asset – operating lease	1,151	1,701
Other assets	6,910	6,910
Total assets	512,243	430,994
Current liabilities
Operating lease liability – current portion	1,163	1,117
Total current liabilities	43,475	28,949
Operating lease liability – net of current portion	0	593
Total liabilities	43,475	29,542
Commitments and Contingencies (Note 7)
Stockholders' equity:
Preferred stock $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025	0	0
Common stock, $0.0001 par value, 500,000,000 shares authorized; 65,931,128 and 56,600,724 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	8	7
Additional paid-in capital	939,940	760,168
Accumulated other comprehensive (loss) income	(567)	243
Accumulated deficit	(470,613)	(358,966)
Total stockholders' equity	468,768	401,452
Total liabilities and stockholders’ equity	512,243	430,994
Nonrelated Party
Current liabilities
Accounts payable	7,431	5,515
Accrued expenses and other current liabilities	33,666	18,898
Related Party
Current liabilities
Accounts payable	1,032	2,278
Accrued expenses and other current liabilities	$ 183	$ 1,141

Marketable Securities - Schedule of Available-For-Sale Securities in an Unrealized Loss Position (Details) $ in Thousands	Jun. 30, 2026 USD ($)
Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]
Less than 12 Months, Fair Value	$ 400,660
Less than 12 Months, Unrealized Losses	(566)
12 Months or Longer, Fair Value	0
12 Months or Longer, Unrealized Losses	0
Total, Fair Value	400,660
Total, Unrealized Losses	(566)
U.S. Treasury Bills
Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]
Less than 12 Months, Fair Value	400,660
Less than 12 Months, Unrealized Losses	(566)
12 Months or Longer, Fair Value	0
12 Months or Longer, Unrealized Losses	0
Total, Fair Value	400,660
Total, Unrealized Losses	$ (566)

Stockholder's Equity	6 Months Ended
Stockholder's Equity	Jun. 30, 2026
Equity [Abstract]
Stockholder's Equity	Stockholder's Equity Preferred Stock The Company has 10,000,000 shares of preferred stock authorized for issuance, par value $0.0001 per share. As of June 30, 2026 and December 31, 2025, no shares of preferred stock were issued or outstanding. Common Stock The Company has 500,000,000 shares of Common Stock authorized for issuance, par value $0.0001 per share. As of June 30, 2026 and December 31, 2025, 65,931,128 and 56,600,724 shares were issued and outstanding, respectively. February 2026 Offering In February 2026, the Company issued and sold 8,581,250 shares of its common stock, including 1,406,250 shares pursuant to the exercise of the underwriters’ option to purchase additional shares, at a price to the public of $16.00 per share, and pre-funded warrants to purchase 2,200,000 shares of common stock (the "pre-funded warrants"), at a public offering price of $15.9999 per pre-funded warrant, which represents the per share public offering price of each share of common stock in the offering, less the $0.0001 per share exercise price for each pre-funded warrant. Pre-funded Warrants Subject to certain requirements, the pre-funded warrants, sold in the Company's February 2026 offering, can be exercised by the holder at anytime. As of June 30, 2026, there have not been any exercises of the pre-funded warrants. The pre-funded warrants meet the criteria to be classified as an equity instrument under ASC 815-40, Derivatives and Hedging — Contracts in Entity’s Own Equity, and funds received were recorded as an increase in additional paid-in capital in the condensed consolidated balance sheets. Funds received upon exercise of warrants will be recorded as common stock in the condensed consolidated balance sheets as the exercise price represents the par value of the underlying common stock. At-The-Market Program On October 3, 2025, the Company filed a shelf registration statement on Form S-3 (the “Registration Statement”), with the SEC covering the offering of up to $400.0 million of common stock, preferred stock, debt securities, warrants and/or units. The Registration Statement was declared effective by the SEC on November 26, 2025. Concurrent with the filing of the Registration Statement, the Company entered into a sales agreement, dated October 3, 2025, by and between the Company and TD Securities (USA) LLC, acting as sales agent, to establish the ATM Program, pursuant to which the Company may offer and sell shares of its common stock from time to time. In connection with the ATM Program, the Company filed a prospectus with the Registration Statement for the offer and sale of up to $150.0 million of shares of common stock from time to time through the sales agent. The Company will pay the agent a commission rate up to 3% of the gross proceeds of any shares sold and has agreed to provide the sales agent with customary indemnification and contributions against certain liabilities. As of June 30, 2026, the Company had remaining available capacity for share issuances of up to $120.0 million under the ATM Program. During the three and six months ended June 30, 2026, there were no sales under the ATM Program.

Leases (Details) $ in Millions	Jun. 03, 2025 USD ($) ft²	Jun. 02, 2025 USD ($) ft²	Jun. 30, 2026 ft²	Oct. 31, 2024 USD ($) ft²	Aug. 16, 2023 ft²
Leases [Abstract]
Lease, term of contract					2 years 6 months
Area of land (in square feet) \| ft²	9,361	9,682	9,361	4,744	4,617
Security deposit				$ 0.1
Lease, base rent	$ 0.6	$ 0.5

Significant Agreements – Related Parties	6 Months Ended
Significant Agreements – Related Parties	Jun. 30, 2026
Related Party Transactions [Abstract]
Significant Agreements – Related Parties	Significant Agreements – Related Parties The Company entered into a master services agreement on December 15, 2020 (the “Master Services Agreement”) with Biocon. Pursuant to the terms of the master service agreement, Biocon provided services related to research and development, clinical trials, regulatory interactions and manufacturing. The Company incurred $0.1 million and $0.0 million expenses under the Master Services Agreement during the three and six months ended June 30, 2026 and 2025, respectively. On July 23, 2019, the Company entered into a contract manufacturing agreement with a wholly-owned subsidiary of Biocon, Biocon Biologics Limited (“BBL”) formerly Biocon Biologics India Limited, which was amended on November 6, 2024 to extend the term of the contract manufacturing agreement until July 23, 2026. Additionally, the Company entered into a material transfer agreement on August 17, 2023, a quality agreement on October 12, 2023, a service agreement on October 18, 2023, and a manufacturing service agreement on December 15, 2023 (collectively, the “BBL Agreements”). Pursuant to the terms of the BBL Agreements, BBL manufactures and supplies specified quantities of products to Bicara to be utilized in research and development and manufacturing as per purchase orders executed from time to time between the two parties. For the three months ended June 30, 2026 and 2025, the Company incurred $0.1 million and $0.0 million of research and development expenses, respectively, under the BBL Agreements. For the six months ended June 30, 2026 and 2025, the Company incurred $0.2 million and $0.0 million of research and development expenses, respectively, under the BBL Agreements. As of June 30, 2026 and December 31, 2025, the Company owed $0.1 million and $0.0 million, respectively. The Company additionally entered into a contract manufacturing agreement with a wholly-owned subsidiary of Biocon, Syngene International Limited (“Syngene”), on July 17, 2019, which was amended and restated on April 1, 2020 with the amended and restated manufacturing service agreement, as amended (the “Syngene Manufacturing Services Agreement”), and a master contract services agreement on July 24, 2020, as amended (the “Syngene Master Contract Services Agreement” and together with the Syngene Manufacturing Services Agreement, the “Syngene Agreements”). Pursuant to the terms of the Syngene Agreements, Syngene manufactures and supplies specified quantities of products to Bicara to be used in research and development as per purchase orders executed from time to time between the two parties and performs additional contract research services under the master contract services agreement. The Syngene Manufacturing Services Agreement expires on the later of October 31, 2027 or the completion of services under all work orders under the agreement. The Syngene Master Contract Services Agreement expires on the later of November 1, 2031 or the completion of all services under the statements of work under the agreement. On December 16, 2024, the Company entered into an additional master contract services agreement with Syngene, whereby Syngene agreed to provide the Company with dedicated research laboratories and personnel (“Dedicated Center Agreement”). The Dedicated Center Agreement expires on the later of December 16, 2028 or the completion of all services under all statements of work under the agreement. For the three months ended June 30, 2026 and 2025, the Company incurred $0.9 million and $2.9 million of manufacturing and research and development expenses, respectively, under the Syngene Agreements. For the six months ended June 30, 2026 and 2025, the Company incurred $2.7 million and $9.5 million of manufacturing and research and development expenses, respectively, under the Syngene Agreements. As of June 30, 2026, and December 31, 2025, the Company owed Syngene $1.0 million and $3.4 million, respectively, relating to these incurred costs, of which $0.9 million and $2.3 million, respectively, were classified in accounts payable-related party and $0.1 million and $1.1 million, respectively, were classified as accrued expenses-related party on the balance sheets.

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2026
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesDeferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. Due to losses incurred since inception and the uncertainty surrounding the realization of the favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against the Company’s otherwise recognizable net deferred tax assets.

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2026
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2026
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Matters From time to time, the Company is involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. The Company makes provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. On October 22, 2024, a complaint was filed in federal district court in the District of Massachusetts by Y-Trap, Inc. ("Y-Trap"), naming as defendants the Company and Biocon Ltd ("Biocon"), captioned Y-Trap, Inc. v. Biocon Ltd and Bicara Therapeutics Inc., No. 24-cv-12678 (D. Mass.). On January 31, 2025, Y-Trap filed its operative amended complaint. The operative complaint alleges a claim against defendants for correction of inventorship of a number of patents based on a license from The Johns Hopkins University, including patents licensed to the Company relating to ficerafusp alfa. The complaint also alleges claims against defendants for unfair trade practices pursuant to Chapter 93A of the Massachusetts General Laws, unjust enrichment, and civil conspiracy. The operative complaint seeks, among other things, damages (including compensatory, enhanced, and punitive damages), an order correcting the inventorship of the patents at issue, costs and attorney’s fees, and other equitable and injunctive relief. On February 28, 2025, Biocon and Bicara moved to dismiss all of Y-Trap’s claims. On September 30, 2025, the court denied Bicara's motion. On October 30, 2025, Bicara answered the operative complaint, and discovery is ongoing. The Company will continue to vigorously defend against this litigation. On July 15, 2026, the Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office instituted a post-grant review petition brought by the Company against The John Hopkins University, No. PGR2026-00025, concerning a patent in a family alleged to be licensed to Y-Trap, U.S. Patent 12,295,968 (“the ’968 patent”). The Company challenges all claims of the ’968 patent under 35 U.S.C. § 112. It is anticipated that the PTAB will issue a final written decision on or before July 14, 2027. The Company does not have contingency reserves established for any litigation liabilities as of June 30, 2026 and December 31, 2025.

Description of Business, Organization, and Liquidity (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended
	Sep. 16, 2024	Feb. 28, 2026	Dec. 31, 2025	Jun. 30, 2026
Subsidiary or Equity Method Investee [Line Items]
Common stock, par value (in usd per share)			$ 0.0001	$ 0.0001
Proceeds from issuance of common stock and accompanying pre-funded warrants, net of issuance costs	$ 332,400
Cash, cash equivalents and investments				$ 497,300
Accumulated deficit			$ 358,966	$ 470,613
Pre-Funded Warrants
Subsidiary or Equity Method Investee [Line Items]
Common stock, par value (in usd per share)		$ 0.0001
IPO
Subsidiary or Equity Method Investee [Line Items]
Number of shares issued in transaction (in shares)	20,125,000
Common stock, par value (in usd per share)	$ 0.0001
Public offering price (in usd per share)	$ 18.00
ATM Program
Subsidiary or Equity Method Investee [Line Items]
Number of shares issued in transaction (in shares)			1,604,000
Common stock, par value (in usd per share)			$ 0.0001
Sale of stock, consideration received on transaction			$ 29,500
February 2026 Offering
Subsidiary or Equity Method Investee [Line Items]
Sale of stock, consideration received on transaction		$ 161,800
February 2026 Offering \| Pre-Funded Warrants
Subsidiary or Equity Method Investee [Line Items]
Class of warrant or right, number of securities called by warrants or rights (in shares)		2,200,000
Class of warrant or right, exercise price of warrants or rights (in usd per share)		$ 15.9999
February 2026 Offering \| Common Equity
Subsidiary or Equity Method Investee [Line Items]
Number of shares issued in transaction (in shares)		8,581,250
Public offering price (in usd per share)		$ 16.00
Over-Allotment Option
Subsidiary or Equity Method Investee [Line Items]
Number of shares issued in transaction (in shares)		1,406,250

Segment Reporting - Schedule Segment Profit or Loss, Including Significant Segment Expenses (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2026	Mar. 31, 2026	Jun. 30, 2025	Mar. 31, 2025	Jun. 30, 2026	Jun. 30, 2025
Segment Reporting [Line Items]
Total general and administrative expenses	$ 14,178		$ 7,220		$ 26,954	$ 14,675
Total operating expenses	59,951		32,018		120,191	73,806
Operating loss	(59,951)		(32,018)		(120,191)	(73,806)
Interest income	4,576		4,682		8,659	9,696
Total other income	4,576		4,682		8,659	9,696
Net income before losses	(55,375)		(27,336)		(111,532)	(64,110)
Net loss	(55,436)	$ (56,211)	(27,388)	$ (36,846)	(111,647)	(64,234)
Reportable Segment
Segment Reporting [Line Items]
Manufacturing and process development	11,484		8,266		34,277	26,921
Clinical operations and development	21,384		10,461		36,311	20,487
Research and development personnel cost and other (including stock-based compensation)	12,469		5,528		21,588	10,624
Research	436		543		1,061	1,099
Total research and development	45,773		24,798		93,237	59,131
General and administrative personnel costs (including stock-based compensation)	8,871		4,854		16,834	9,686
Professional fees	4,677		1,392		8,960	2,896
Facility costs, IT, office expense and other	630		974		1,160	2,093
Total general and administrative expenses	14,178		7,220		26,954	14,675
Total operating expenses	59,951		32,018		120,191	73,806
Operating loss	(59,951)		(32,018)		(120,191)	(73,806)
Interest income	4,576		4,682		8,659	9,696
Total other income	4,576		4,682		8,659	9,696
Net income before losses	(55,375)		(27,336)		(111,532)	(64,110)
Income tax expense	(61)		(52)		(115)	(124)
Net loss	$ (55,436)		$ (27,388)		$ (111,647)	$ (64,234)

Stock-Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions		6 Months Ended
	Sep. 05, 2024	Jun. 30, 2026	Jun. 30, 2025	Jan. 31, 2026
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average fair value of options granted (in usd per share)		$ 13.98	$ 12.16
Aggregate intrinsic value of options exercised		$ 11.5	$ 0.8
Unvested stock options outstanding (in shares)		7,914,415
Unrecognized compensation costs		$ 71.1
Common Stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized share-based compensation cost, period of recognition (in years)		3 years
Employee Stock
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)	507,383
Number of additional shares allowable under the plan (in shares)	1,014,766
Percent of outstanding shares	1.00%
2024 Stock Option And Grant Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares authorized for issuance (in shares)		2,453,616
Percentage of increase in future issuance reserved share		5.00%
Expiration period (in years)		10 years
2024 Stock Option And Grant Plan \| Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period (in years)		1 year
2024 Stock Option And Grant Plan \| Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period (in years)		4 years
2024 Stock Option And Grant Plan \| Incentive Stock Options And Non-Qualified Stock Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option shares issued (in shares)		5,552,037
2026 Inducement Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)		700,000		1,000,000

Segment Reporting - Narrative (Details)	6 Months Ended
Segment Reporting - Narrative (Details)	Jun. 30, 2026 segment
Segment Reporting [Abstract]
Number of reportable segments	1

Cover Page - shares	6 Months Ended
Cover Page - shares	Jun. 30, 2026	Aug. 06, 2026
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2026
Document Transition Report	false
Entity File Number	001-42271
Entity Registrant Name	BICARA THERAPEUTICS INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	83-2903745
Entity Address, Address Line One	116 Huntington Ave
Entity Address, Address Line Two	Suite 703
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02116
City Area Code	617
Local Phone Number	468-4219
Title of 12(b) Security	Common Stock, par value $0.0001
Trading Symbol	BCAX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		66,172,934
Entity Central Index Key	0002023658
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2026
Document Fiscal Period Focus	Q2
Amendment Flag	false

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Operating activities:
Net loss	$ (111,647)	$ (64,234)
Adjustments to reconcile net loss to cash used in operating activities:
Stock-based compensation	14,096	6,943
Depreciation	88	38
Non-cash lease expense	550	349
Net amortization of premiums and discounts on marketable securities	575	0
Changes in operating assets and liabilities:
Prepaid expenses and other assets	689	4,743
Operating lease liabilities	(547)	(323)
Net cash used in operating activities	(81,714)	(53,700)
Investing activities:
Purchase of marketable securities	(244,929)	0
Proceeds from maturities and sales of marketable securities	161,000	0
Purchase of property and equipment	(120)	0
Net cash used in investing activities	(84,049)	0
Financing activities:
Proceeds from issuance of common stock and accompanying pre-funded warrants, net of issuance costs	161,763	0
Proceeds from exercise of options	3,914	595
Net cash provided by financing activities	165,677	595
Net decrease in cash and cash equivalents	(86)	(53,105)
Cash and cash equivalents at beginning of period	96,685	489,711
Cash and cash equivalents at end of period	96,599	436,606
Supplemental disclosure of cash flow information:
Cash paid for taxes	155	124
Non-cash investing and financing activities:
Right-of-use asset obtained in exchange for lease liability	0	1,878
Vesting of early exercise stock options	0	17
Nonrelated Party
Changes in operating assets and liabilities:
Accounts payable and accrued expenses	16,686	(2,715)
Related Party
Changes in operating assets and liabilities:
Accounts payable and accrued expenses	$ (2,204)	$ 1,499

Significant Agreements (Details) $ in Thousands	3 Months Ended		6 Months Ended
Significant Agreements (Details) $ in Thousands	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Apr. 30, 2026 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2022 USD ($)	Jun. 30, 2021 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other commitment, liability, refundable deposit, amount	$ 1,900		$ 1,900			$ 1,900
Total operating expenses	59,951	$ 32,018	120,191	$ 73,806
IQVIA RDS Inc \| Master Clinical Contract Services Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Initial payment amount					$ 12,800			$ 1,800
Total operating expenses	17,300	8,800	27,100	16,800
Amount paid	9,200	$ 5,200	16,900	$ 17,500
Accounts payable	1,300		1,300			400
Accrued expenses and other current liabilities	$ 20,000		$ 20,000			$ 8,600
IQVIA RDS Inc \| Master Clinical Contract Services Agreement, Refundable Deposit
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Initial payment amount								1,000
IQVIA RDS Inc \| Master Clinical Services Agreement, Investigator Grant Payment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Initial payment amount					7,300			$ 800
IQVIA RDS Inc \| Master Clinical Contract Services Agreement, Additional Refundable Deposit
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Initial payment amount							$ 900
IQVIA RDS Inc \| Master Clinical Contract Services Agreement Deposits For Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Initial payment amount					4,500
IQVIA RDS Inc \| Master Clinical Contract Services Agreement Deposit For Pass Through Costs
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Initial payment amount					$ 1,000
IQVIA RDS Inc \| Master Clinical Contract Services Agreement Incremental Return
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other commitment percentage					0.75

Marketable Securities - Narrative (Details) - debtSecurity	Jun. 30, 2026	Dec. 31, 2025
Investments, Debt and Equity Securities [Abstract]
Number of securities held in unrealized loss position	19	0

Leases	6 Months Ended
Leases	Jun. 30, 2026
Leases [Abstract]
Leases	Leases On August 16, 2023, the Company entered into a 2.5 year lease for 4,617 square feet of office space in Boston, Massachusetts (the “Lease Agreement”). In October 2024, the Company amended its Lease Agreement to lease an additional 4,744 square feet of office space in order to expand the Company’s headquarters to 9,361 square feet of office space. The lease required a security deposit totaling $0.1 million, which the Company has met with cash on deposit. On June 2, 2025, the Company entered into a Sublease Agreement (the “Sublease”) with J.W. Childs Associates, L.P., as sublandlord, effective on June 4, 2025. Under the Sublease, the Company leased approximately 9,682 square feet of additional office space as part of its corporate headquarters, through June 30, 2027. The base rent of the Sublease is approximately $0.5 million per year. The Sublease required an immaterial security deposit, which the Company has satisfied with cash on deposit. On June 3, 2025, the Company entered into a second amendment to the Lease Agreement (the Lease Agreement, together with all amendments, the “Amended Lease”) to extend the term for the 9,361 square feet of office space leased under the Amended Lease through June 30, 2027. The modification of the Lease Agreement required the Company to remeasure the value of the asset and liability in accordance with ASC 842, Leases. The base rent under the Amended Lease continues to be approximately $0.6 million per year. The remeasurement did not have a material impact on the Company's right-of-use assets.

Fair Value Measurements (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	$ 488,492	$ 411,711
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	87,832	93,595
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	400,660	318,116
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	0	0
U.S. Treasury Bills
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds included within cash and cash equivalents	400,660	318,116
U.S. Treasury Bills \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds included within cash and cash equivalents	0	0
U.S. Treasury Bills \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds included within cash and cash equivalents	400,660	318,116
U.S. Treasury Bills \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds included within cash and cash equivalents	0	0
Money market funds included within cash and cash equivalents
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds included within cash and cash equivalents	87,832	93,595
Money market funds included within cash and cash equivalents \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds included within cash and cash equivalents	87,832	93,595
Money market funds included within cash and cash equivalents \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds included within cash and cash equivalents	0	0
Money market funds included within cash and cash equivalents \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds included within cash and cash equivalents	$ 0	$ 0